| Literature DB >> 30340321 |
Petra Borilova Linhartova1,2, Denisa Kavrikova3, Marie Tomandlova4, Hana Poskerova5, Vaclav Rehka6, Ladislav Dušek7, Lydie Izakovicova Holla8,9.
Abstract
Chronic periodontitis (CP) and diabetes mellitus (DM) involve several aspects of immune functions, including neutrophil activity and cytokine biology. Considering the critical function of chemokine interleukin-8 (IL-8) in the inflammatory process, the aims of this study were to determine: (i) IL-8 plasma levels; (ii) IL-8 (-251A/T, rs4073) and its receptor 2 (CXCR2, +1208C/T, rs1126579) polymorphisms, and (iii) the presence of the selected periodontal bacteria in types 1 and 2 DM patients (T1DM and T2DM) and systemically healthy controls (HC) with known periodontal status. This case⁻control study comprises of 153 unrelated individuals: 36/44 patients suffering from T1DM+CP/T2DM+CP and 32/41 from HC+CP/non-periodontitis HC. Both the clinical and biochemical parameters were monitored. The genotypes were determined using qPCR, IL-8 plasma levels were measured using an ELISA kit. Subgingival bacterial colonization was analyzed with a DNA microarray detection kit. The IL-8 plasma levels differed significantly between non-periodontitis HC and T1DM+CP/T2DM+CP patients (P < 0.01). Even in HC+CP, IL-8 concentrations were significantly lower than in T1DM+CP/T2DM+CP patients (P ≤ 0.05). No significant associations between the IL-8 plasma levels and the studied IL-8 and CXCR2 polymorphisms or the occurrence of selected periodontal bacteria (P > 0.05) were found. CP does not influence the circulating IL-8 levels. Patients with T1DM+CP/T2DM+CP had higher circulating IL-8 levels than HC+CP/non-periodontitis HC.Entities:
Keywords: chemokines; chronic periodontitis; diabetes mellitus; interleukin-8; plasma; polymorphism
Mesh:
Substances:
Year: 2018 PMID: 30340321 PMCID: PMC6214016 DOI: 10.3390/ijms19103214
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Demographic data for the studied T1DM+CP and T2DM+CP patients as well as HC+CP and non-periodontitis HC.
| Characteristics | Non-Periodontitis HC | HC+CP | T1DM+CP | T2DM+CP |
|---|---|---|---|---|
| Age (years) | 45.5 ± 9.6 | 59.5 ± 9.3 * | 49.7 ± 10.4 | 66.8 ± 8.5 * |
| Duration of DM (years) | 0.0 ± 0.0 | 0.0 ± 0.0 | 25.1 ± 11.8 | 10.2 ± 7.7 |
| DM control (well/satisfactorily/unsatisfactorily controlled) % | − | − | 0.0/8.3/91.7 | 7.7/28.2/64.1 |
| Sex (males) % | 31.3 | 26.8 | 44.4 | 40.9 |
| Smoking (yes) % | 5.3 | 19.4 | 25.0 * | 7.1 ‡,§ |
| DN (yes) % | 0.0 | 0.0 | 27.6 | 16.7 |
| DR (yes) % | 0.0 | 0.0 | 63.3 ‖ | 0.0 |
| DPN (yes) % | 0.0 | 0.0 | 50.0 ‖ | 9.3 |
| BMI | 23.8 ± 4.2 | 26.8 ± 3.9 | 25.1 ± 3.1 | 29.9 ± 7.7 *,§ |
| GI | 0.3 ± 0.2 | 0.9 ± 0.3 † | 1 ± 0.3 † | 1.1 ± 0.3 † |
| PD (mm) | 0.6 ± 0.2 | 3.3 ± 0.9 * | 3.6 ± 0.9 † | 3.8 ± 1.0 † |
| AL (mm) | 0.8 ± 0.2 | 4.1 ± 1.1 † | 4.4 ± 1.5 † | 4.7 ± 1.2 † |
| N of sites with PD ≥ 5 mm | 0 | 18 ± 17 * | 20 ± 19 * | 20 ± 16 * |
| N of teeth with PD ≥ 5 mm | 0 | 10 ± 7 * | 11 ± 7 * | 11 ± 6 * |
| N of sites with AL ≥ 5 mm | 0 | 32 ± 21 * | 38 ± 28 * | 38 ± 19 * |
| N of teeth with AL ≥ 5 mm | 0 | 15 ± 7 * | 15 ± 7 * | 15 ± 6 * |
| HbA1c (mmol/mol) | - | - | 69.6 ± 12.0 | 57.7 ± 14.5 § |
| Blood glucose (mmol/L) | 5.4 ± 0.5 | 5.7 ± 0.3 | 7.5 ± 2.3 | 7.7 ± 2.4 |
| Total cholesterol (mmol/L) | - | - | 4.7 ± 0.7 | 4.7 ± 1.0 |
| Triglycerides (mmol/L) | - | - | 1.0 ± 0.6 | 2.0 ± 1.2 |
| LDL (mmol/L) | - | - | 2.7 ± 0.6 | 2.7 ± 0.9 |
| HDL (mmol/L) | - | - | 1.6 ± 0.4 | 1.3 ± 0.3 |
− = unknown. Note: In T1DM+CP patients, the diabetic control was known only in 31 of them. * P < 0.05 in comparison to non-periodontitis HC. † P < 0.01 in comparison to non-periodontitis HC. ‡ P < 0.05 in comparison to HC+CP individuals. § P < 0.05 in comparison to T1DM+CP patients. ‖ P < 0.01 in comparison to T2DM+CP patients. DM: diabetes mellitus; DN: diabetic nephropathy; DR: diabetic retinopathy; DPN: diabetic neuropathy; BMI: body mass index; GI: gingival index; PD: pocket depth; AL: attachment loss; LDL: low density lipoprotein; HDL: high density lipoprotein.
Figure 1Comparison of IL-8 plasma levels in T1DM+CP (N = 36) and T2DM+CP patients (N = 44) and HC+CP (N = 41) and non-periodontitis HC (N = 32). Samples with IL-8 levels under the limit of detection (<4.40 pg/mL) were assigned a value of 4.39 pg/mL. The Mann-Whitney U-test (two-tail) was used for the calculation of significant differences.
Comparison of IL-8 plasma levels in diabetic patients according to their glycemic control.
| IL-8 Levels, Median [IQR] in pg/mL | ||
|---|---|---|
| Well Controlled | Satisfactorily Controlled | Unsatisfactorily Controlled |
| 12.68 | 14.45 | 14.04 |
Note: In T1DM+CP patients, the diabetic control was known only in 31 of them. IQR: interquartile range.
Comparison of IL-8 plasma levels in T2DM patients according to their BMI.
| IL-8 Levels, Median [IQR] in pg/mL | ||
|---|---|---|
| Normal Weight | Overweight | Obese BMI > 30 kg/m2
|
| 12.68 | 13.75 | 14.04 |
IQR: interquartile range.
IL-8 plasma levels and polymorphisms in IL-8 and CXCR2 genes *.
| SNPs Genotypes | IL-8 Levels, Median [IQR] in pg/mL | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Periodontitis HC | HC+CP | T1DM+CP | T2DM+CP | T2DM+CP Subgroups | |||||||||
| Well/Satisfactorily Controlled | Unsatisfactorily Controlled | ||||||||||||
| TT | 10 | 9.20 | 10 | 10.36 | 11 | 13.16 | 16 | 13.75 | 5 | 12.87 | 11 | 14.33 | |
| AT | 15 | 11.00 | 21 | 7.68 | 16 | 17.38 | 17 | 14.18 | 6 | 15.10 | 11 | 13.49 | |
| AA | 7 | 10.86 | 10 | 12.19 | 9 | 13.33 | 10 | 15.80 | 5 | 16.69 | 5 | 14.04 | |
| CC | 9 | 11.28 | 14 | 12.30 | 9 | 17.89 | 17 | 15.09 | 7 | 15.36 | 10 | 14.88 | |
| CT | 17 | 9.09 | 18 | 11.57 | 20 | 14.00 | 21 | 13.16 | 7 | 14.18 | 14 | 13.16 | |
| TT | 6 | 11.43 | 9 | 6.99 | 7 | 12.00 | 5 | 16.69 | 2 | 18.48 | 3 | 13.49 | |
* Genotypes are known only in 152 participants as one DNA sample was of poor quality.
IL-8 plasma levels and periodontal bacteria in a subgroup of 140 individuals.
| Bacteria (%) | IL-8 Levels, Median [IQR] in pg/mL | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Periodontitis HC | HC+CP | T1DM+CP | T2DM+CP | T2DM+CP Subgroups | ||||||||
| Well/Satisfactorily Controlled | Unsatisfactorily Controlled | |||||||||||
| 0.0 | - | 2.4 | 46.40 | 0.0 | - | 2.3 | 30.86 | 0.0 | - | 3.7 | 30.86 | |
| 100.0 | 10.21 | 97.6 | 10.80 | 100.0 | 15.09 | 97.7 | 14.18 | 100.0 | 15.36 | 96.3 | 13.77 | |
| 68.4 | 10.21 | 48.8 | 7.80 | 55.6 | 18.41 | 38.6 | 13.49 | 29.4 | 28.16 | 44.4 | 13.33 | |
| 31.6 | 10.14 | 51.2 | 13.45 | 44.4 | 13.25 | 61.4 | 15.09 | 70.6 | 14.77 | 55.6 | 15.09 | |
| 68.4 | 9.73 | 14.6 | 13.18 | 25.0 | 24.33 | 22.7 | 14.26 | 17.6 | 12.33 | 25.9 | 16.24 | |
| 31.6 | 10.54 | 85.4 | 10.57 | 75.0 | 12.00 | 77.3 | 14.26 | 82.4 | 16.36 | 74.1 | 13.77 | |
| 36.8 | 8.61 | 2.4 | 46.40 | 8.3 | 24.33 | 0.0 | - | 0.0 | - | 0.0 | - | |
| 63.2 | 11.67 | 97.6 | 10.80 | 91.7 | 13.33 | 100.0 | 14.26 | 100.0 | 15.36 | 100.0 | 14.04 | |
| 47.4 | 8.77 | 14.6 | 14.83 | 25.0 | 20.87 | 22.7 | 13.33 | 17.6 | 12.87 | 25.9 | 13.49 | |
| 52.6 | 10.93 | 85.4 | 10.15 | 75.0 | 12.00 | 77.3 | 14.50 | 82.4 | 16.36 | 74.1 | 14.19 | |
| 31.6 | 9.89 | 2.4 | 46.40 | 0.0 | - | 0.0 | - | 0.0 | - | 0.0 | - | |
| 68.4 | 10.21 | 97.6 | 10.80 | 100.0 | 15.09 | 100.0 | 14.26 | 100.0 | 15.36 | 100.0 | 14.04 | |
| 47.4 | 8.77 | 41.5 | 7.99 | 41.7 | 17.89 | 45.5 | 14.08 | 35.3 | 11.76 | 51.9 | 15.05 | |
| 52.6 | 10.54 | 58.5 | 11.57 | 58.3 | 12.00 | 54.5 | 14.26 | 64.7 | 20.27 | 48.1 | 13.49 | |
Neg: negative; pos: positive. * P < 0.05 in comparison of IL-8 plasma levels between patients negative and positive for the specific bacteria (P > 0.05).